Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
| العنوان: | Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia |
|---|---|
| المؤلفون: | Yi‐Jiun Su, Ming‐Chung Kuo, Tsai‐Yun Chen, Ming‐Chung Wang, Youngsen Yang, Ming‐Chun Ma, Tung‐Liang Lin, Tung‐Huei Lin, Hung Chang, Chieh‐Lin Jerry Teng, Pei‐Ching Hsiao, Chih‐Cheng Chen, Po‐Nan Wang, Lee‐Yung Shih |
| المصدر: | Cancer Science. 113:3518-3527 |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cancer Research, Oncology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Dasatinib, Fusion Proteins, bcr-abl, Imatinib Mesylate, Humans, General Medicine, Protein Kinase Inhibitors, Retrospective Studies |
| الوصف: | Several studies have compared the molecular responses between e14a2 and e13a2 BCR::ABL1 transcripts in chronic myeloid leukemia (CML) patients treated with front-line imatinib, but there were very limited studies on nilotinib or dasatinib-treated patients. We retrospectively analyzed the molecular responses in 1124 CML patients with the e14a2 or e13a2 transcript receiving front-line imatinib, nilotinib or dasatinib treatment. Patients with the e14a2 transcript had higher optimal response rates than those with the e13a2 transcript at 12 months in the imatinib-treated group, and 6 and 12 months in the nilotinib-treated group. The optimal response rates were not significantly different between the two transcripts in the dasatinib-treated group at landmark molecular responses. With a median follow-up time of 48.4 months, higher cumulative incidences of BCR::ABL1 International Scale ≤1% and major molecular response were observed in patients with the e14a2 rather than the e13a2 transcript receiving front-line imatinib or nilotinib treatment, but not in dasatinib-treated patients. The progression-free survival and overall survival did not differ between the two transcripts in all three treatment groups. In view of the speed and depth of molecular responses, BCR::ABL1 transcript subtypes might provide helpful information in selecting a front-line tyrosine kinase inhibitor for individual young patients with future potential treatment-free remission. |
| تدمد: | 1349-7006 1347-9032 |
| DOI: | 10.1111/cas.15501 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89e87e2150d5c2e47c09e48b4d21b131 https://doi.org/10.1111/cas.15501 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....89e87e2150d5c2e47c09e48b4d21b131 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13497006 13479032 |
|---|---|
| DOI: | 10.1111/cas.15501 |